MAGE-A3-specific anticancer immunotherapy in the clinical practice

Brichard, Vincent G.; Godechal, Quentin

doi:10.4161/onci.25995

Cited by 15 publications

(11 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, the use of AS15 was associated with 4 objective responses, a 6-mo PFS rate of 25%, and a median overall survival (OS) of 33 mo, while that of AS02B resulted in 1 objective response, a 6-mo PFS rate of 14% and an OS of 19.9 mo. All patients developed anti-MAGEA3 antibodies, yet their levels were 3-fold higher in the AS15 arm, corroborating the superior immunostimulatory and clinical activity of this preparation 115 , 116 . Interestingly, the authors also identified a 84-gene signature associated with clinical benefit among AS15-treated and less so AS02B-treated patients.…”

Section: Literature Updatementioning

confidence: 67%

Trial Watch

et al. 2014

View full text Add to dashboard Cite

Toll-like receptors (TLRs) are an evolutionarily conserved group of enzymatically inactive, single membrane-spanning proteins that recognize a wide panel of exogenous and endogenous danger signals. Besides constituting a crucial component of the innate immune response to bacterial and viral pathogens, TLRs appear to play a major role in anticancer immunosurveillance. In line with this notion, several natural and synthetic TLR ligands have been intensively investigated for their ability to boost tumor-targeting immune responses elicited by a variety of immunotherapeutic and chemotherapeutic interventions. Three of these agents are currently approved by the US Food and Drug Administration (FDA) or equivalent regulatory agencies for use in cancer patients: the so-called bacillus Calmette-Guérin, monophosphoryl lipid A, and imiquimod. However, the number of clinical trials testing the therapeutic potential of both FDA-approved and experimental TLR agonists in cancer patients is stably decreasing, suggesting that drug developers and oncologists are refocusing their interest on alternative immunostimulatory agents. Here, we summarize recent findings on the use of TLR agonists in cancer patients and discuss how the clinical evaluation of FDA-approved and experimental TLR ligands has evolved since the publication of our first Trial Watch dealing with this topic.

show abstract

Section: Literature Updatementioning

confidence: 67%

Trial Watch

et al. 2014

View full text Add to dashboard Cite

show abstract

“…CT83 with the MAGE family (MAGE‐A1, MAGE‐A3, MAGEH1, MAGE‐A9, MAGE‐C1/CT7, and MAGE‐C2/CT10) and NY‐ESO‐1, the most prevalently expressed antigens in spontaneous humoral to mediate T cell responses, has been described in tumor patients . Shida et al reported that CT83 expression was observed in gastric cancer, while the frequency of CT83 expression (81.6%) was higher than that of the MAGE‐A1 (34.7%), MAGE‐A3 (44.9%), and NY‐ESO‐1(16.3%).…”

Section: Discussionmentioning

confidence: 99%

“…[21][22][23] CT83 with the MAGE family (MAGE-A1, MAGE-A3, MAGEH1, MAGE-A9, MAGE-C1/CT7, and MAGE-C2/ CT10) and NY-ESO-1, the most prevalently expressed antigens in spontaneous humoral to mediate T cell responses, has been described in tumor patients. [24][25][26][27][28] Shida et al 14 reported that CT83 expression was observed in gastric cancer, while the frequency of CT83 expression (81.6%) was higher than that of the MAGE-A1 (34.7%), MAGE-A3 (44.9%), and NY-ESO-1(16.3%). It was worth noting that even in patients with stage I gastric cancers, the CT83 expression rate (79.4%) was high, suggesting that CT83 was a potential biomarker for early diagnosis of gastric cancer.…”

Section: Discussionmentioning

confidence: 99%

Targeted photodynamic therapy of cancer using a novel gallium (III) tris (ethoxycarbonyl) corrole conjugated‐mAb directed against cancer/testis antigens 83

Liang

et al. 2018

Cancer Medicine

View full text Add to dashboard Cite

Photodynamic therapy (PDT) is a noninvasive, highly selective approach to the treatment of tumors. However, its therapeutic effect is limited by long‐lasting skin phototoxicity. Therefore, to compromise this shortcoming, it is preferable to deliver photosensitizers selectively to tumor cells with the aid of antibodies specific against tumor‐associated antigens. Cancer/testis antigens 83 (CT83), also called KK‐LC‐1 or CXorf61, recognized by cytotoxic T lymphocytes (CTL), has become a promising target for immunotherapy. Herein, we developed and characterized a novel mouse CT83 mAb 7G4 with a high affinity with Gallium (III) 5, 10, 15‐tris (ethoxycarbonyl) corrole (1‐Ga), a new and promising photosensitizer in PDT. The enzyme‐linked immunosorbent assay (ELISA), flow cytometry and cytotoxicity activity assays revealed that 7G4‐1‐Ga was able to recognize human CT83 with high specificity. Furthermore, 7G4‐1‐Ga showed greater cytotoxicity to CT83‐expressing human cancer cells in vitro than 1‐Ga. These results suggest that the antibody‐conjugated photosensitizer between anti‐CT83 mAb and 1‐Ga may have a good application in PDT, where the destruction of CT83‐expressing tumor is required.

show abstract

“…Eight of these trials involve Imlygic Ò , three Cavatak TM , three Reolysin Ò , two HF10, two MV-NIS, two CG0070 (a conditionally replicating oncolytic adenovirus genetically modified to express GM-CSF), 121,248 two Toca 511 (an amphotropic replication-competent retrovirus genetically modified to express an enzyme that converts inactive 5-fluorocytosine into active 5-fluorouracil), [249][250][251][252] and the remaining six various oncolytic viruses including G207, JX-594, OBP-301, DNX-2401 (an oncolytic adenovirus engineered to replicate in cells exhibiting defects in cell cycle control, previously known as Delta-24-RGD or Delta-24-RGD-4C), [253][254][255] MG1-MA3 (an attenuated version of the Maraba rhabdovirus, further engineered to express the TAA melanoma antigen family A3, MAGEA3), 85,256,257 and Ad5-yCD/mutTKSR39rep-hIL12 (an oncolytic adenovirus endowed with an increased cytolytic potential and the ability to express human IL-12) 106,258,259 (Table 1).…”

Section: Recently Initiated Clinical Trialsmentioning

confidence: 99%

Trial Watch—Oncolytic viruses and cancer therapy

et al. 2015

View full text Add to dashboard Cite

Oncolytic virotherapy relies on the administration of non-pathogenic viral strains that selectively infect and kill malignant cells while favoring the elicitation of a therapeutically relevant tumor-targeting immune response. During the past few years, great efforts have been dedicated to the development of oncolytic viruses with improved specificity and potency. Such an intense wave of investigation has culminated this year in the regulatory approval by the US Food and Drug Administration (FDA) of a genetically engineered oncolytic viral strain for use in melanoma patients. Here, we summarize recent preclinical and clinical advances in oncolytic virotherapy.

show abstract

MAGE-A3-specific anticancer immunotherapy in the clinical practice

Cited by 15 publications

References 9 publications

Trial Watch

Trial Watch

Targeted photodynamic therapy of cancer using a novel gallium (III) tris (ethoxycarbonyl) corrole conjugated‐mAb directed against cancer/testis antigens 83

Trial Watch—Oncolytic viruses and cancer therapy

Contact Info

Product

Resources

About